Novel medications for the irritable bowel syndrome: motility and sensation.
Camilleri
M
M
Enteric Neuroscience Program, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
D015746:Abdominal Pain / Q000188:drug therapy; D000818:Animals; D002243:Carbolines / Q000009:adverse effects / Q000627:therapeutic use*; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D003248:Constipation / Q000150:complications; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D012737:Sex Factors
D002243:Carbolines; D005765:Gastrointestinal Agents; D007211:Indoles; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C090840:alosetron; C105050:tegaserod